You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Leading medical-scientific event on Hemophilia held in Trieste, Italy

Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight

read more 

EVENTS

Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy

A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN

read more 

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 
  1. CORPORATE - 25-08-2017

    Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

    The product is approved for post-exposure prophylaxis against rabies infection

    read more 
  2. EVENTS - 14-07-2017

    Kedrion Biopharma attends XXVI ISTH Congress in Berlin, Germany

    A crowded symposium dedicated to the SIPPET Study was held on July 9th

    read more 
  3. EVENTS - 22-05-2017

    Farmindustria roadshow is hosted by Kedrion

    Innovation and Production of Value held on 19th May at our Bolognana production plant

    read more 
  4. EVENTS - 27-04-2017

    Kedrion Biopharma joins IPOPI in celebrating World PI Week 2017

    Global campaign to improve early diagnosis and optimal treatments for PID

    read more 

Pages

For more information please contact: pressoffice@kedrion.com